Cargando…
Loss of MTSS1 results in increased metastatic potential in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival rate of 7%. This dismal prognosis is largely due to the inability to diagnose the disease before metastasis occurs. Tumor cell dissemination occurs early in PDAC. While it is known that inflammation facilitates this process, the underlyin...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369978/ https://www.ncbi.nlm.nih.gov/pubmed/28146435 http://dx.doi.org/10.18632/oncotarget.14869 |
_version_ | 1782518160774135808 |
---|---|
author | Zeleniak, Ann E Huang, Wei Brinkman, Mary K Fishel, Melissa L Hill, Reginald |
author_facet | Zeleniak, Ann E Huang, Wei Brinkman, Mary K Fishel, Melissa L Hill, Reginald |
author_sort | Zeleniak, Ann E |
collection | PubMed |
description | Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival rate of 7%. This dismal prognosis is largely due to the inability to diagnose the disease before metastasis occurs. Tumor cell dissemination occurs early in PDAC. While it is known that inflammation facilitates this process, the underlying mechanisms responsible for this progression have not been fully characterized. Here, we functionally test the role of metastasis suppressor 1 (MTSS1) in PDAC. Despite evidence showing that MTSS1 could be important for regulating metastasis in many different cancers, its function in PDAC has not been studied. Here, we show that loss of MTSS1 leads to increased invasion and migration in PDAC cell lines. Moreover, PDAC cells treated with cancer-associated fibroblast-conditioned media also have increased metastatic potential, which is augmented by loss of MTSS1. Finally, overexpression of MTSS1 in PDAC cell lines leads to a loss of migratory potential in vitro and an increase in overall survival in vivo. Collectively, our data provide insight into an important role for MTSS1 in suppressing tumor cell invasion and migration driven by the tumor microenvironment and suggest that therapeutic strategies aimed at increasing MTSS1 levels may effectively slow the development of metastatic lesions, increasing survival of patients with PDAC. |
format | Online Article Text |
id | pubmed-5369978 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-53699782017-04-17 Loss of MTSS1 results in increased metastatic potential in pancreatic cancer Zeleniak, Ann E Huang, Wei Brinkman, Mary K Fishel, Melissa L Hill, Reginald Oncotarget Research Paper Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival rate of 7%. This dismal prognosis is largely due to the inability to diagnose the disease before metastasis occurs. Tumor cell dissemination occurs early in PDAC. While it is known that inflammation facilitates this process, the underlying mechanisms responsible for this progression have not been fully characterized. Here, we functionally test the role of metastasis suppressor 1 (MTSS1) in PDAC. Despite evidence showing that MTSS1 could be important for regulating metastasis in many different cancers, its function in PDAC has not been studied. Here, we show that loss of MTSS1 leads to increased invasion and migration in PDAC cell lines. Moreover, PDAC cells treated with cancer-associated fibroblast-conditioned media also have increased metastatic potential, which is augmented by loss of MTSS1. Finally, overexpression of MTSS1 in PDAC cell lines leads to a loss of migratory potential in vitro and an increase in overall survival in vivo. Collectively, our data provide insight into an important role for MTSS1 in suppressing tumor cell invasion and migration driven by the tumor microenvironment and suggest that therapeutic strategies aimed at increasing MTSS1 levels may effectively slow the development of metastatic lesions, increasing survival of patients with PDAC. Impact Journals LLC 2017-01-27 /pmc/articles/PMC5369978/ /pubmed/28146435 http://dx.doi.org/10.18632/oncotarget.14869 Text en Copyright: © 2017 Zeleniak et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Zeleniak, Ann E Huang, Wei Brinkman, Mary K Fishel, Melissa L Hill, Reginald Loss of MTSS1 results in increased metastatic potential in pancreatic cancer |
title | Loss of MTSS1 results in increased metastatic potential in pancreatic cancer |
title_full | Loss of MTSS1 results in increased metastatic potential in pancreatic cancer |
title_fullStr | Loss of MTSS1 results in increased metastatic potential in pancreatic cancer |
title_full_unstemmed | Loss of MTSS1 results in increased metastatic potential in pancreatic cancer |
title_short | Loss of MTSS1 results in increased metastatic potential in pancreatic cancer |
title_sort | loss of mtss1 results in increased metastatic potential in pancreatic cancer |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369978/ https://www.ncbi.nlm.nih.gov/pubmed/28146435 http://dx.doi.org/10.18632/oncotarget.14869 |
work_keys_str_mv | AT zeleniakanne lossofmtss1resultsinincreasedmetastaticpotentialinpancreaticcancer AT huangwei lossofmtss1resultsinincreasedmetastaticpotentialinpancreaticcancer AT brinkmanmaryk lossofmtss1resultsinincreasedmetastaticpotentialinpancreaticcancer AT fishelmelissal lossofmtss1resultsinincreasedmetastaticpotentialinpancreaticcancer AT hillreginald lossofmtss1resultsinincreasedmetastaticpotentialinpancreaticcancer |